Nu Skin Enterprises Stock Price and Value Analysis

Nu Skin Enterprises (NYSE:NUS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Nu Skin Enterprises to reach your target.

Target type

NUS Free Cash Flow Trend

Free Cash Flow trendline for NUS
Free Cash Flow trendline for Nu Skin Enterprises
CSV

Based on historical returns, we believe that Nu Skin Enterprises can grow its free cash at a rate of about 15%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a great rate!
  • This company is solid.
  • This stock is available at a great discount!
  • This company has a large dividend yield!
  • This company has wild ups and downs.

Inside the NUS Numbers

NUS Price
(Nu Skin Enterprises stock price per share)
$3.80
[?] NUS Fair Price
(based on intrinsic value)
$245.67
[?] NUS Safety Price (based on a variable margin of safety) $159.69
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 76% lower than other Healthcare stocks
[?] PE Ratio versus Industry 95% higher than other Medical Distribution stocks
[?] Cash Yield 182.08%
[?] Free Cash Flow Jitter 86%
[?] Dividend Yield 6.37% (tax impact)
Shares Shorted 4,457,541

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,457,541 shares shorted. With 47,317,505 shares available for purchase and an average trading volume over the past 10 trading days of 716,130, it would take at least 6.2 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 1021561 87.3
2009 1021561 116
2010 1021561 158
2011 1021561 191
2012 1021561 265
2013 1021561 451
2014 1021561 -152
2015 1021561 226
2016 1021561 177
2017 1021561 212
2018 1021561 135
2019 1021561 117
2020 1021561 317
2021 1021561 75.8
2022 1021561 42.5
2023 1021561 55.4
2024 1021561 53.4
2025 1021561 27.9

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $3,542 million against net income of $2,533 million, or 1.40 times. Net income was negative in 1 of the 18 years, and those years are left out of the ratio.

In 2025, operating cash flow was 0.50 times net income, compared with 1.46 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $34.3 million, 42.7% of operating cash flow of $80.3 million, which leaves an estimated $46 million after capex. Across the 17 years with reported capex, it averaged 28.1% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 0.50, below 0.80, so under 80% of reported net income arrived as operating cash and at least 0.25 under the 1.46 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 65.3 103 16 1.58
2009 89.8 134 20.2 1.49
2010 136 188 53.8 1.38
2011 153 224 41.8 1.46
2012 222 311 96.6 1.40
2013 365 530 185 1.45
2014 189 -56.5 101 -0.30
2015 133 322 56.6 2.42
2016 143 275 50.2 1.92
2017 129 303 60.2 2.34
2018 122 203 70.4 1.66
2019 174 178 66.1 1.03
2020 191 379 63.8 1.98
2021 147 142 68.6 0.96
2022 105 108 59.1 1.03
2023 8.6 119 58.5 13.80
2024 -147 112 41.6 n/a
2025 160 80.3 34.3 0.50

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $1,213 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $650 million, 53.6% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 7 of those 10 years.

In 8 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $716 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $31.9 million, 114.3% of estimated free cash flow of $27.9 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 177 78.4 247 326 183.7%
2017 212 76.1 71.7 148 69.8%
2018 135 80.6 69.6 150 111.2%
2019 117 82.2 0.8 83 70.8%
2020 317 78.4 144 223 70.3%
2021 75.8 76.3 80.4 157 206.8%
2022 42.5 77 70 147 346.2%
2023 55.4 77.6 13 90.6 163.5%
2024 53.4 11.9 n/a 11.9 22.3%
2025 27.9 11.8 20 31.9 114.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,331 million in 2009 and $1,485 million in 2025, a compound annual growth rate of 0.7% over 16 years.

Revenue fell 14.3% from 2024 to 2025.

Our estimated free cash flow was $27.9 million in 2025, 1.9% of revenue. In 2009 the estimated margin was 8.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 1,331 116 8.7%
2010 1,537 158 10.3%
2011 1,720 191 11.1%
2012 2,132 265 12.4%
2013 3,177 451 14.2%
2014 2,569 -152 -5.9%
2015 2,247 226 10.0%
2016 2,208 177 8.0%
2017 2,279 212 9.3%
2018 2,679 135 5.0%
2019 2,420 117 4.8%
2020 2,582 317 12.3%
2021 2,696 75.8 2.8%
2022 2,226 42.5 1.9%
2023 1,969 55.4 2.8%
2024 1,732 53.4 3.1%
2025 1,485 27.9 1.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $239 million against total liabilities of $600 million, or 39.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 42.7% of total assets in 2025, compared with 49.8% in 2009, a decrease of 7.1 percentage points.

Stockholders equity was $805 million in 2025, compared with $376 million in 2009, a rise of 114.3%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.1% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 748 158 373 376
2010 892 230 421 471
2011 991 273 417 574
2012 1,125 320 534 591
2013 1,821 525 962 859
2014 1,614 288 672 942
2015 1,506 289 680 826
2016 1,474 357 810 664
2017 1,590 426 885 705
2018 1,694 387 913 782
2019 1,769 336 894 875
2020 1,957 403 1,063 894
2021 1,906 340 994 913
2022 1,821 265 924 897
2023 1,809 256 987 822
2024 1,469 187 817 651
2025 1,405 239 600 805

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $3.80, the price is below what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 14.6 percent a year for this stock. This is not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $337 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $3.04 below range
Current price $3.80 below range
20 percent above the current price $4.56 below range
Our model (stored fair price) $245.67 14.6%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Nu Skin Enterprises reported positive free cash flow in 17 of the 18 fiscal years we have from its current SEC filer.

At $3.80, Nu Skin Enterprises trades below our safe value estimate of $159.69 and our fair value estimate of $245.67.

Average free cash flow over the last three years of data was $45.6 million, and across the first three years it was $120 million; over the period it fell sharply.

Year-to-year variability in free cash flow is volatile, measured at 86%.

Nu Skin Enterprises yields 6.37% in dividends.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 76% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 95% above the average for stocks in the Medical Distribution industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Distribution industry, the ones closest in market capitalization to Nu Skin Enterprises, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Nu Skin Enterprises (NUS) 185 - 6.4% 182.1% 98% below
Herbalife Nutrition Ltd. (HLF) 1,629 9.1 - 39.8% 97% below
SiteOne Landscape Supply (SITE) 4,646 28.4 - - 180% above
Henry Schein (HSIC) 9,232 22.9 - 7.3% 44% below
McKesson Corporation (MCK) 123,473 27.6 0.3% 3.3% 30% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1021561.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: NUS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in NUS

Does Nu Skin Enterprises have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: NUS

This example shows how we apply the Trendshare checklist to NUS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 3.80
    • Market cap: $185M
    • EPS: -4.86
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 182.1%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.